MSF Hits Back At ViiV Over ‘Infuriating’ Cabotegravir Approach

Welcomes MPP Deal For Generics, But Calls For More Transparency From Originator

 
• By David Wallace
  
MSF logo on website through magnifying glass
MSF has criticized ViiV over cabotegravir • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin